Objective: To determine (a) the proportion of asymptomatic infants born at X35 weeks gestation evaluated for early-onset sepsis (EOS) and exposed to postnatal antibiotics; (b) reasons for and outcomes of the evaluations, and (c) anticipated changes when applying the Centers for Disease Control and Prevention (CDC) 2010 guidelines to this study population.
Introduction
The Centers for Disease Control and Prevention (CDC) guidelines for the use of intrapartum antibiotic prophylaxis (IAP) to prevent perinatal Group B Streptococcus (GBS) infection have led to a significant decrease in the incidence of both overall and GBSspecific neonatal early-onset sepsis (EOS). [1] [2] [3] Among infants born at the Brigham and Women's Hospital, a large maternity center in Boston, MA, we observed a 40% decrease in the overall incidence of neonatal EOS with the use of a screening-based approach to GBS prevention. 4 The CDC guidelines for the prevention of neonatal GBS disease were initially published in 1996, revised in 2002 and most recently revised in November 2010. [5] [6] [7] Each guideline contains recommendations that impact obstetrical and neonatal workflow and resource utilization. All versions provide recommendations for the evaluation of newborns for EOS of all bacterial causes, including evaluation criteria for the lowest-risk category of infants, asymptomatic infants born at or near term gestation. The 2002 criteria included evaluation and empiric treatment of infants born to women with chorioamnionitis, and those infants born to women who did not receive indicated GBS prophylaxis; indications for evaluating infants for inadequate GBS IAP were restricted in the 2010 revision. The clinical diagnosis of 'chorioamnionitis' is left to local interpretation, but includes maternal intrapartum fever, uterine tenderness, fetal tachycardia, maternal tachycardia and foul-smelling or purulent amniotic fluid. 7 The rationale for evaluating infants born in the setting of chorioamnionitis is based on histological and epidemiological studies demonstrating an increased risk of EOS in the presence of chorioamnionitis; [8] [9] [10] multiple studies inform the risk of GBS-specific EOS in the absence of intrapartum prophylaxis. 11 Decisions regarding local care practices and resource utilization for neonatal EOS evaluations would be best made with quantitative information on the prevalence of risk factors for EOS and the frequency of empiric antibiotic administration. Approximately 3-4% of births are complicated by maternal fever >38.0 1C alone, 12 but few data inform the combined impact of all indications for EOS evaluation in the era of GBS prophylaxis, particularly among infants who appear healthy at birth. The objectives of our study were to quantify the number of wellappearing infants who are evaluated for EOS, using a local algorithm aligned with the CDC 2002 guidelines, and to estimate how this would change when applying the recommendations contained in the CDC 2010 revision. We studied the distribution of reasons for EOS evaluation, the use of empiric antibiotics and the outcomes of CBC and blood culture testing over a 12-month period in 2008-2009 at our institution. . These time periods were chosen to reflect the most recent obstetrical care practices, and were separated in time to minimize the impact of secular trends. At our institution, all infants meeting criteria for a sepsis evaluation are seen in the neonatal intensive care unit (NICU). Asymptomatic infants evaluated for EOS in the first 48 h of life were identified by review of NICU admission log. Eligible infants met all of the following criteria: (a) gestational age at birth X35 weeks; (b) evaluation for EOS within the first 48 h of life; (c) asymptomatic or 'well-appearing' status as defined by admission to the NICU triage evaluation area solely for the presence of intrapartum EOS risk factors; an observation period of 1-4 hours in the triage area; and transfer to the newborn nursery after EOS evaluation. At our institution, infants requiring care beyond a period of 4 h are transferred out of the NICU triage evaluation area and admitted to the NICU. Exclusion criteria included: EOS evaluation performed for signs of illness (that is, respiratory distress, hypoglycemia, cyanosis or apnea), and/or admission to the NICU due to signs of illness. Clinical and microbiological information were obtained by review of infant and maternal medical records. Maternal antibiotic exposure was assessed for the hospital admission leading to delivery. Annual live birth and neonatal intensive care admission data were obtained from hospital summary statistics.
Methods

Case ascertainment and chart review
Blood culture methods and identification
Blood cultures were performed in the Brigham and Women's Hospital microbiology laboratory with an automated BACTEC system. Both aerobic and anaerobic bottles are used for routine newborn culture. Cases of culture-proven EOS were identified by query of the microbiology laboratory's electronic database for any blood culture positive for a bacterial species obtained from an infant before 48 h of age. Positive cultures were considered to be a case of EOS, if all of the following criteria were met: (a) the culture grew a known pathogenic species (that is, GBS, E. coli), (b) the attending neonatologist considered the infant to be infected and (c) the infant was treated with an appropriate course of antibiotics (X7 days). Cultures growing in common skin flora (that is, Bacillus species, diphtheroids, coagulase-negative staphylococci) were considered contaminants if the infant remained well in the absence of appropriate antibiotic treatment.
EOS evaluation criteria and methods
During the study period, asymptomatic infants born at X35 weeks gestation were evaluated for EOS using an algorithm based on the 2002 CDC GBS guideline 6 ( Figure 1 ). This algorithm incorporated maternal GBS status and IAP for GBS, as well as peripartum risk factors for overall EOS, including maternal fever, chorioamnionitis, duration of rupture of membranes (ROM), gestational age (GA) and sustained fetal tachycardia. Sepsis evaluations included a physical exam, complete blood counts (CBCs) and blood cultures. An abnormal white blood cell (WBC) count was defined as total WBC <5000, or I/T ratio >0.2 (I/T ratio defined as the proportion of immature neutrophil forms divided by the sum of mature and immature neutrophils). The CDC 2002 algorithm for newborn evaluation recommends empiric antibiotic treatment, if maternal chorioamnionitis was present, but does not provide a firm definition for this primarily clinical diagnosis. For the purpose of administering empiric antibiotics to asymptomatic infants at highest risk, our center defined chorioamnionitis as maternal intrapartum fever X1011F; or maternal fever X100.41F in addition to another risk factor or clinical sign ( Figure 1 ). This definition was made in consultation with our obstetrical colleagues. In addition, empiric antibiotics were administered if the WBC or differential was abnormal ( Figure 1 ). Well-appearing infants received the first doses of antibiotics after EOS evaluation in the NICU triage evaluation area, and were subsequently transferred to the Newborn Nursery, where they completed at least 48 h of antibiotics until final blood culture results were reported.
Results
Frequency of EOS evaluations
The derivation of the study population is outlined in Figure 2 . It consisted of 1062 infants, representing 14.7% of all infants born at X35 weeks gestation, clinically well enough to be cared for in the newborn nursery. Demographic information for the study population is shown in Table 1 .
Reasons for EOS evaluation and empiric antibiotic treatment
The distribution of reasons for EOS evaluations is shown Table 2 . Maternal fever X100.4 prompted 70.4% of the evaluations; the majority of the remaining evaluations were performed for inadequate GBS prophylaxis. Of those evaluated for infection, 55.4% were treated with antibiotics; concern for chorioamnionitis was the primary reason for treatment (Table 3) .
Role of the complete blood count in EOS evaluation
The CDC 2002 guidelines for EOS evaluation recommend obtaining neonatal CBC and WBC differential. The guidelines do not provide standards for interpretation of these laboratory values. Of the 1062 CBC's obtained during the study, 41% were obtained at <1 h of life; 43% were obtained at 1-4 h of life; 2% were obtained at >4 h of life and in 13%, the exact time could not be determined. The distribution of values obtained for total WBC, I/T as well as for absolute neutrophil count are shown in Figure 3 . As defined in the algorithm used during the study period, only 32/1062 CBC's had abnormal WBC values: one with total WBC <5000, and 31 with I/T ratios X0.2. Abnormal WBC values alone prompted empiric antibiotic treatment in only 5/32 infants as most of the infants with abnormal WBC values met other criteria for treatment. None of the 32 infants with abnormal WBC values had blood culture-proven infection.
Culture-proven EOS during the study period
We examined all cases of EOS among infants born at X35 weeks gestation during our study period, including infections that were diagnosed among infants who presented with and had a sepsis evaluation performed because of symptoms of illness. Six infants born at X35 weeks gestation were found to have blood cultureproven EOS (Table 4) (incidence 0.76 cases/1000 live births). None had CSF culture-proven meningitis; in one case (#4), the CSF cell counts suggested meningitis. In only 1/6 infected infants was any component of the initial WBC abnormal (case #1, I/T ¼ 0.6). Of the six infants with culture-proven EOS, three were evaluated for symptoms; the remaining cases occurred among the wellappearing infants evaluated on the basis of risk factors (incidence 2.8 cases/1000 evaluated infants). Two of the three asymptomatic infants were treated empirically with antibiotics before the identification of bacteremia and both remained clinically well. In the remaining infant, the constellation of risk factors did not meet criteria for treatment per the algorithm. This infant remained in 
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Newborn Nursery until the blood culture was flagged positive for GBS at 13-h incubation. When reevaluated in the NICU to obtain repeat blood culture and lumbar puncture, the infant was noted to be tachypneic and briefly required supplemental oxygen. The repeat blood culture obtained 18 h after the first also grew GBS.
Potential impact of the CDC 2010 revised guidelines A significant change in the CDC 2010 revision pertinent to newborn EOS evaluation was the recommendation to evaluate infants for inadequate IAP, only if additional risk factors were present, including maternal intrapartum fever, birth at <37 weeks gestation or duration of ROM >18 h. 7 To estimate the effect, this recommendation might have on work flow in our center, we assessed how many of the 1062 evaluations performed during the study period would be altered. We determined that 274/1062 evaluations (25.8%) were performed in the absence of maternal fever, solely for inadequate indicated GBS IAP (Table 2 ). Of these, gestational age <37 weeks was present in 22 infants. Among the 266/274 women for whom duration of ROM was known, the mean duration of ROM was 1.7 h ( ± 2.8). Duration of ROM >18 h was present in only eight infants born X37 weeks gestation. Thus 244/ 274 (89%) of EOS evaluations performed solely for inadequate GBS IAP would be eliminated under a revised local algorithm consistent with the CDC 2010 guidelines, reducing the total number of EOS evaluations performed by 23%.
Discussion
Neonatal caregivers must decide how to approach risk for EOS in an era where the disease is infrequent. Issues to be considered must balance the potentially fatal consequences of missing a diagnosis of EOS until an infant is critically ill, the financial impact of performing evaluations, the social impact of separating mothers and newborns to perform evaluations and administer antibiotics, and the undefined potential for long-term consequences of administering antibiotics to large numbers of uninfected newborns. Our findings inform the relative inefficiency of currently recommended algorithms for evaluating neonatal EOS, and demonstrate the considerable burden these evaluations have in the care of newborns. Asymptomatic status was an important negative predictor of blood-culture proven infection within an at-risk neonatal cohort. 10 We chose to limit our study to asymptomatic infants born at X35 weeks gestation as these infants are at lowest baseline risk and thus potentially a population where evaluation Abbreviation: CBC, complete blood count.
Neonatal early onset sepsis evaluations S Mukhopadhyay et al could be safely limited. Our study suggests several areas for improvement in the evaluation of these infants. Nearly 15% of all asymptomatic term and late preterm infants were evaluated for EOS, using an algorithm consistent with the CDC 2002 recommendations. The algorithm did enrich for infected infants in that the incidence of culture-proven EOS was 2.8 cases/ 1000 among the 1062 evaluated infants compared with 0.76 cases/ 1000 among all 7943 infants born at X35 weeks gestation. This approach identified half of the blood culture-proven EOS cases that occurred during our study period; however, it resulted in B350 evaluations performed per identified bacteremia. Symptomatic infants provided the other three casesFand somewhat more efficiently, with three cases found among 717 symptomatic infants (B240 evaluations per identified bacteremia).
Our algorithm recommended empiric antibiotic therapy for infants predicted to be at highest risk for EOS due to higher maternal fever, or to a clustering of risk factors with lower maternal fever. Maternal fever was a common occurrence; 9.4% of infants in the entire study cohort were born to mothers with intrapartum temperature X100.41F (38 1C). Two-thirds of EOS evaluations were prompted by the presence of maternal fever, nearly 80% of which met our criteria for empiric antibiotic therapy. Whether empiric administration of antibiotics shortly after birth is an entirely benign practice is of increasing concern. Studies performed among premature infants demonstrate that antibiotic therapy in the first week of life is associated with increased risk of fungal infection, bacterial late-onset sepsis, necrotizing enterocolitis and death. [13] [14] [15] [16] These studies may not be relevant to the health of well-appearing term infants receiving short courses of antibiotics. However, a prospective, longitudinal birth cohort study performed in Sweden found that exposure to antibiotics in the first week of life was associated with increased risk of recurrent wheezing disorders by age 12 months, and this risk persisted through 4.5 years of age. 17, 18 The association remained strong when the cohort was restricted to infants born at X37 weeks gestation. 17 In addition, single doses of aminoglycosides such as gentamicin can cause permanent and severe hearing loss in genetically predisposed individuals. The prevalence of this predisposition is reported to range from 1/520 to 1/1161 infants. 19 Finally, emerging data suggest effects of early antibiotic exposures on the development of the intestinal microbiome, and on subsequent risk of gastrointestinal disease. 20 CDC guidelines state that maternal fever can be used as a surrogate for chorioamnionitis, and support the use of empiric neonatal antibiotics for these reasons. Given the frequency of intrapartum fever found in our study, the infrequent occurrence of bacteremia among initially asymptomatic term and late preterm infants, and concern for the safety of unnecessary antibiotic exposure, it is clear that the development of better approaches to identify infants at highest risk is needed. We recently demonstrated that using a multivariate model for EOS risk may provide a means for such an improvement. 21 Our study found that a quarter of EOS evaluations were performed in the absence of maternal fever, solely for inadequate GBS prophylaxis. Very few of these evaluations involved additional risk factors defined for consideration in the CDC 2010 revised guideline (GA <37 weeks or ROM <18 h). This is perhaps not surprising; in our local experience, most inadequate IAP derives from women at term who deliver quickly, which results in decreased opportunity for the development of ascending fetal colonization and infection. Indeed, we found the mean duration of ROM among the mothers whose infants were evaluated owing to inadequate GBS IAP was <2 h. We show that 23% of EOS evaluations in our center may be eliminated by revision of our local algorithm to align with the CDC 2010 guideline. The recommendations regarding evaluation of infants for inadequate GBS IAP may then represent an opportunity for eliminating neonatal evaluation of very low-risk infants. However, this Neonatal early onset sepsis evaluations S Mukhopadhyay et al approach has not been universally accepted. In a statement recommending algorithms for neonatal EOS evaluation among term infants, the American Academy of Pediatrics Committee on the Fetus and Newborn supports EOS evaluation of infants born at X37 weeks gestation with inadequate GBS prophylaxis or with ROM X18 h. 22 Our local data suggests that elimination of evaluation for inadequate GBS IAP can be done safely. In a review of GBS bacteremia occurring at our center over the past 14 years, we identified only three cases associated with inadequate prophylaxis in the absence of additional risk factors. 23 (and unpublished data) The low risk associated with GBS colonization in the absence of additional risk factors was demonstrated in early GBS prophylaxis studies. In the first randomized study of IAP in GBS-colonized women delivering at term, among babies delivered to women without fever or prolonged ROM who did not receive IAP, the incidence of GBS bacteremia was only 0.4 cases/1000 births. 24 It is important to note that the CDC guidelines also recommend that infants born under these circumstances be closely observed for the development of clinical signs of infection.
A final opportunity to improve the efficiency of the neonatal EOS evaluation may lie in the appropriate use of the CBC to make decisions regarding empiric antibiotic treatment among asymptomatic infants. A previous study demonstrated that optimal use of the WBC and its components should consider interval likelihood ratios in the initial hours of newborn life, with the most predictive value deriving from results obtained after 4 h of age. 25 That study of nearly 68 000 infants did not consider infant clinical status in developing the likelihood ratios. The CDC 2010 revised guideline state that CBC's may be obtained at 6-12 h of life rather than at birth. 7 The current study supports a delay in obtaining CBC data among initially asymptomatic infants. At least 84% of the 1062 WBC and differential values were obtained before 4 h of life, and only 3% were abnormal. Most important, in <0.5% of cases did the WBC results alone determine whether empiric antibiotic treatment was given.
One difficulty in improving the identification of newborns at risk for EOS continues to be the occurrence of GBS bacteremia among infants born to mothers who screen GBS negative. 23, 26 Both cases of GBS infection in our study period occurred in newborns born to GBS-negative mothers. Rescreening of GBS-negative women with real-time nucleic-acid amplification testing at presentation for delivery could impact this problem, although the cost-effectiveness of such an approach remains to be determined. The primary use of nucleic-acid amplification testing rather than culture-based GBS screening is not widely validated and nor endorsed by CDC. 7 GBS vaccines are not currently available, but may ultimately present the safest and most efficient approach to neonatal GBS prevention.
Our study has several limitations. The study was conducted at a large maternity center where >95% of delivering women receive Note: fifteen infants (1.4% of the study cohort) initially transferred to newborn nursery were later admitted to the neonatal intensive care unit (NICU) for a variety of indications: respiratory distress consisting of tachypnea or desaturation episodes (nine); neonatal abstinence syndrome (two) and one case each with hypoglycemia; hypothermia; seizure; failed car seat test. Only one of these infants (case #6 above) had a positive blood culture.
Neonatal early onset sepsis evaluations S Mukhopadhyay et al prenatal care, and GBS screening results are almost universally available at presentation for delivery. We did not collect data on the use of epidural anesthesia during labor that may influence the incidence of intrapartum fever. 27 However, the use of epidural anesthesia is very common in our center, where nearly 70% of deliveries utilize epidural anesthesia. 28 Finally, obstetrical policies regarding the administration of intrapartum antibiotics for GBS prophylaxis, for intrapartum fever and for perioperative prophylaxis are determined by the faculty obstetric practice and strictly enforced among all delivering clinicians (including obstetrical residents, private obstetricians and midwives), resulting in very uniform intrapartum antibiotic exposures. Each of these factors may limit how our study findings could be applied to centers that care for women who receive incomplete prenatal care, and/or centers with different obstetrical antibiotic and anesthesia practices.
Conclusions
Using the CDC 2002 Guidelines, nearly 15% of initially asymptomatic infants born at X35 weeks gestation were evaluated for neonatal EOS, primarily because of the presence of maternal intrapartum fever or inadequate administration of indicated GBS IAP. Of those evaluated, over half were treated with antibiotics. CBC results obtained shortly after birth provide little additional information in the management of these infants. Adherence to the CDC 2010 guidelines would be expected to eliminate approximately a quarter of EOS evaluations. Further improvements in the care of these infants may come from delay or elimination of CBC determinations, and by the development of improved methods of distinguishing at-risk infants.
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